ParcelBio

About

ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.

Founders

• 
  David Weinberg· Founder

  David is the co-founder and CEO of ParcelBio. He was previously VP of RNA Platform at Orbital Therapeutics / Circ Bio, where he led the development of a circular RNA therapeutics platform. Before that, he was Sr. Director of Molecular Research at Freenome, where he built the multiomics diagnostics platform that enabled a blood test for the early detection of cancer​. David obtained his PhD from MIT, was a UCSF Faculty Fellow, and has been honored with Forbes ‘30 Under 30’ and an NIH DP5 Award.

  LinkedIn ↗
• 
  Chris Carlson· Founder

  Chris is the co-founder and CSO of ParcelBio. He was previously a scientist at Orbital Therapeutics, where he was the primary contributor on multiple patents regarding stabilization of therapeutic RNAs. Chris obtained his PhD from UCSF where he studied RNA packaging and protection in viruses.

  LinkedIn ↗

Change history · none recorded